Session 1. Advances in cardiovascular therapeutics. Chairman: Juan Tamargo. Universidad Complutense de Madrid.

1. Juan Tamargo. Universidad Complutense de Madrid.  Diabetes and Heart Failure: Therapeutic role of
   glifozines..
2. Luis Rodríguez Padial. Complejo Hospitalario de Toledo. New approaches to the treatment of thrombosis.
3. Ricardo Caballero. Universidad Complutense de Madrid. Treatment of dyslipidemias.
4. Sofia Miñano. Universidad de Granada. Role of immune cells mitochondrial metabolism in the development of cardiovascular
   complications in a murine model of lupus induced by TLR7 activation.

Session 2. Neuropharmacology. Chairman: José Manuel Brea. Universidad de Santiago de Compostela.

1. Asia Fernández Carvajal. Universidad Miguel Hernández de Elche. New pharmacological approaches to treat alterations in the sensory nervous system.
2. Olga Valverde Granados. Universidad Pompeu Fabra. Modulatory effects of endocannabinoids on cocaine seeking behavior in mice.
3. Rebeca Diez-Alarcia. Universidad del País Vasco: Inverse agonism and functional selectivity on serotonin 5-HT2A receptors. Relevance for the design of new antipsychotic drugs.
4. Mabel Loza. Universidad de Santiago de Compostela. Novel in vitro phenotypic models in
   neuropharmacology.

Session 3. Cardiovascular Pharmacology. Chairman: Carlos Sánchez-Ferrer. Universidad Autónoma de Madrid.

1. Concha Peiró. Universidad Autónoma de Madrid. Angiotensin-(1-7), a novel anti-aging drug for the vasculature?.
2. Susana Novella. Universidad de Valencia. MicroRNA as potential modulators of cardiovascular function of estradiol.
3. Ana Paula Dantas. Universidad de Barcelona. Estrogen receptor in cardiovascular protection: the good, the bad and the ugly.
4. Patrice Marques. Universidad de Valencia. Platelet hyperactivity as trigger of platelet-leukocyte-endothelium interactions and subsequent cardiovascular complications in early-stage COPD.
   
5. Miguel Angel Olivencia. Universidad Complutense de Madrid. Novel role of hydrogen
   sulfide in erectile dysfunction: Regulation of guanylyl cyclase – redox state.

Session 4. Lectures by 2020-2023 SEF Awards to young researchers.

2020. Marta Toral. Aortic disease in Marfan syndrome is caused by overactivation of sGC-PRKG signaling by nitric oxide.
2021. Jesús Cosín. Role of metabolite-sensing GPCRs in Inflammatory Bowel Disease: Relevance of Intestinal Microbiota.
2022. Gema Mondéjar. Investigating the Risk of Prolonged Repolarization and Arrhythmogenesis Associated with Fentanyl Abuse Using Human iPSC-derived Cardiomyocytes
2023. Iñaki Robles Vera. Translocation of gut microbiota induce trained immunity in bone marrow progenitor cells

Session 5. Nanopharmacology: a new era in therapeutics. Chairman: Valentín Ceña. Universidad de Castilla-La Mancha.

1. Valentín Ceña. Universidad de Castilla-La Mancha. Role of siRNA and nanoparticles in glioblastoma treatment.
2. Barbara Klajnert-Maculewicz. University of Lodz. Dendrimers in neurodegenerative disorders – an overview.
3. Jean-Pierre Majoral. CNRS. Phosphorus dendrimers as nanocarriers or drugs active per se. Selected recent advances.
4. Helena Tomás. University of Madeira.  Dendrimer-based nanomaterials for anticancer drug delivery.
   

Session 6. Teaching and creativity in Pharmacology. Chairwoman: Rosario Jiménez. Universidad de Granada.

1. Michael Spedding. IUPHAR. 50 years of young pharmacology: managing and guarding creativity.
2. Francisco Pérez Vizcaíno. Universidad Complutense de Madrid. Database for multiple choice tests in Pharmacology. Platform for the automatic generation of exams.
3. Carmen Montesinos Mezquita. Universidad de Valencia. Benefits of a collaborative teaching network for improved Pharmacology education.
4.  Francisco Nieto. Universidad de Granada. Demonstrating the placebo effect to  pharmacology students. 

Session 7. Teaser poster session.  Chairman: Antonio Rodríguez-Artalejo. Universidad Complutense de Madrid.

1. J. Rodrigues. University of Madeira. Dendritic Ruthenium-based Anticancer Nanosystems: multi-step synthesis procedures
   coming to life.
2. I. Valencia. Universidad Autónoma de Madrid. Vascular smooth muscle cells-derived extracellular vesicles are conveyors of NLRP3 inflammasome and mediate inflammation in diabetes.
3. C.González-Correa. Universidad de Granada. The probiotic Lactobacillus fermentum CECT5716 increases the antihypertensive response of hydrochlorothiazide in spontaneously hypertensive rats.
4. E. Domingo. Universidad de Valencia. Deletion of CCR3 receptor in apoE−/− mice subjected to an atherogenic diet accelerates atherosclerosis.
5. A.L. Martínez. Universidad de Santiago. A Novel Model for HTS of Drugs for Post-Acute Sequelae of COVID-19 -Related Neuronal Damage.
6. A. Bellver Sanchis. Universidad de Barcelona. Neuroprotective effects of G9a inhibition through modulation of PPARγ/GADD45α-dependent pathways by miR-128.
7. A. Antolín. Bellvitge Biomedical Research Institute – IDIBELL. The major metabolite of the PARP inhibitor rucaparib exhibits unique PLK2 inhibition unlocking a new anti-Parkinson strategy.
8. R. Muñoz-García. Universidad de Sevilla. Dietary Oleacein attenuates Lupus Nephritis in Balb/C Pristane-Induced.
9. I. Gayo-Abeleira. Universidad de Alcalá. Ménière disease and interleukin 17A.
10. R.M. Giner. Universidad de Valencia. Transferosomes loaded with cyanocobalamin effectively reduce oedema associated with atopic dermatitis in an in vivo assessment using a hypersensitivity mouse model.
11. C. Costas. Universidad de Lugo. Neurotoxic Shellfish Poisoning: Brevetoxin 3 acute toxicity in vivo.
12. J. E. Baños. Universidad de Vic. The (mis)use of scientific discourse to legitimize drug promotion in the opioid crisis in the US. An analysis for teaching purposes using TV series Dopesick.

Session 8: New perspectives in neuropharmacology. Chairwoman: Mercè Pallás. Universidad de Barcelona.

1. Enrique J. Cobos. Universidad de Granada. Sigma-1 receptors and pain: modulation of peripheral sensitization.
2. Julia García-Fuster. Universidad de les Illes Balears. Characterizing novel antidepressants for adolescent psychopathology from a preclinical perspective.
3. Mercè Pallas. Universidad de Barcelona. I2 imidazoline receptors: validation as a target for Alzheimer’s disease treatment.
4. Inmaculada Posadas. Universidad de Castilla-La Mancha. Engineered Neutral Phosphorous Dendrimers Protect Mouse Cortical Neurons and Brain Organoids from Excitotoxic Death.
5. Antonio Rodríguez-Artalejo. Universidad Complutense de Madrid. From chromaffin cells to primary nociceptive neurons: a round trip from stress to pain.

Session 9. Pulmonary fibrosis: new challenges. Chairwoman: María Jesús Sanz. Universidad de Valencia.

1. Ana Montes. Bellvitge Biomedical Research Institute – IDIBELL. Pathobiological features of idiopatic pulmonar fibrosis.
2. Javier Milara. Universidad de Valencia. Emerging Therapeutic Targets for idiopatic pulmonar fibrosis.
3. Paula Montero. Universidad de Valencia. Experimental Models in idiopatic pulmonar fibrosis.
4. C. Griñán Ferré. Universidad de Barcelona. Discovery of a Dual-Action of G9a Inhibitors for the Treatment of Alzheimer’s Disease.
5. María Jesús Sanz. Universidad de Valencia. Normalization of metabolic and inflammatory parameters in vitro and in vivo in ob/ob mice by a novel pan-PPAR agonist (BP-2).